cells ANN-1 and AbNRK, the SFFV nonproducer cells SFFV-NIH and SFFV-NRK, a SV40-transformed rat embryo fibroblast line SVRE 17, and an A-MuLV-transformed BALB/c lymphoid line 18-4 have been described elsewhere (22 25) . Cell cultures were also prepared from 14-16-d BALB/c and B6 fetuses.
Mixed Lymphocyte Cultures. B6 spleen cells were incubated either alone or with an equal number of mitomycin C-treated BALB/c spleen cells in Mishell-Dutton medium supplemented with 2% fetal bovine serum (FBS) and 5 × 10 -5 M 2-mercaptoethanol. After 70, 96, and 120 h, six replicate cultures of stimulated and nonstimulated spleen cells were each incubated at 37 °C for 6 h with 1 /~Ci of [methyl-3H]thymidine (80 Ci/mmol). Uptake of [3H] thymidine was maximum at 96 h, at which time stimulated cells incorporated 16-fold more thymidine (135,790 + 5305 cpm) than did unstimulated cells (8,488 + 1865 
cpm).
Antisera and Cytotoxicity Tests. Goat antisera directed against Rauscher murine leukemia virus structural proteins p15, pr65, and gpT0 were obtained from R. Wilsnack through the offices of the Special Virus Cancer Program, NCI, NIH. The antisera B6 anti-B6T1, (C3H X B6)Fx anti-B6T1, B6 anti-B6Mo3, and BALB/c anti-EL4 were prepared as described (22, 26) . The antiserum B6 anti-A-MuLV was prepared according to the method described for B6 anti-FV (23) . Monoclonal Thy-1 antibody was purchased from New England Nuclear, Boston, MA, and used in direct cytotoxicity tests (22) at dilutions of 10 .3 to 10 -5 or in absorption tests at a dilution of 10 .2 .
Radioisotopic Labeling of Cells. Subconfluent monolayers of fibroblasts or 10 v nonadherent cells were incubated at 37°C for 2-4 h with 200-400 #Ci of [SSS]methionine (700-1,300 Ci/ mmol) in RPMI 1640 medium lacking methionine and supplemented with 10% dialyzed FBS. Cells were also labeled for 2.5 h with 500/zCi [a2p]orthophosphate in phosphate-free RPMI 1640 medium supplemented with 10% dialyzed FBS. For experiments with tritiated sugar precursors, cells were incubated at 37°C for 2 h with 250/zCi of [aH]glucosamine (38 Ci/mmol) or [aH]mannose (7.2 Ci/mmol) in glucose-free minimum essential medium. Incoporation of radiolabel was terminated by the addition of 0.25 volumes of 5)< lysis buffer (0.05 M NaHPO4, pH 7.2, 4.5% NaCI, 5% Triton X-100, 2.5% sodium deoxycholate, 0.5% sodium dodecyl sulfate (SDS), and 5% Trasylol (protease inhibitor)). Cell extracts were incubated with nonimmune mouse serum for 1 h, and then, after the addition of formalin-fixed Staphylococcus aureus bacteria, Cowan strain I (27) , the lysates were centrifuged at 120,000 g for 90 min. The resulting supernatant was used in subsequent immunoprecipitation reactions as described.
Cells in phosphate-buffered saline were radioiodinated by the lactoperoxidase method (28), washed in 10 mM KI-phosphate-buffered saline, and resuspended in 0.8 ml hypotonic buffer (10 mM Tris-HC1, pH 7.4, 10 mM NaC1, 1.5 M MgCIz). Lysates were then prepared as above.
Immunoprecipitation and SDS-Polyac~ylamide Gel Analysis. Cell extracts (1-20 × 10 ° cpm) were incubated with 1-10 ~1 of goat or mouse antiserum at 4°C for at least 1 h. Immune complexes were collected by the addition of 200 #1 of a 10% vol/vol solution of the S. aureus bacteria in RIPA buffer (3) followed by centrifugation. After four washes with RIPA buffer, immune complexes were solubilized by heating at 100°C for 5 min in sample buffer (26) .
Immunoprecipitated proteins were electrophoresed through 10% SDS-polyacrylamide slab gels as described (29) . After fixation and staining, gels that contained either 3SS-or 3H-labeled proteins were prepared for fluorography (30) , dried, and exposed to X-omat R Kodak film 32 125
(Eastman Kodak Co., Rochester, NY). Gels containing P-or I-labeled proteins were dried and exposed to X-omat R Kodak film in the presence of an intensifying screen. All gels contained the standard marker proteins RNA polymerase subunits (160K, 150K, 90K, 36.5K), fl-galactosidase (116K), phosphorylase A (96K), bovine serum albumin (68K), and ovalbumin (43K).
Tryptic Peptide Analysis. Immunoprecipitated proteins were resolved on preparative cylindrical gels. Proteins were eluted from appropriate gel slices and trypsinized according to the method of Kew et al. (31) . Peptides were applied to a column of Technicon Chromobeads type P cation exchange resin, and the chromatogram was developed with a linear gradient of pyridine acetate, increasing in pH and concentration (0.2 M, pH 3.1, to 2 M, pH 5.0) for the first 200 fractions. The column was then washed with 2 M pyridine acetate (pH 5.0) for the final 50 fractions (31) .
Results

Identification of Novel Proteins in A-MuLV Lymphomas That Cease Expression of the A-MuL V Gag-Fusion Protein.
We recently observed that continued in vivo propagation of some A-MuLV lymphomas results in the appearance of tumor cells that are different from most A-MuLV lymphoma cells in the expression of the A-MuLVencoded gag-fusion protein (19) . Tumor cells recovered after several in vivo passages (p 12-p45) no longer synthesized detectable amounts of the A-MuLV-encoded gagfusion protein p 160, although this protein was readily detectable in earlier transplants (0-5) of the same tumors (32) .
To detect other tumor-specific proteins synthesized by these unusual p 160-negative cells, B6 mice were immunized with tumor cells from late transplant generations (p15-p45) of the A-MuLV-induced lymphoma, B6T1, referred to as B6TI(L) cells. Extracts of B6T 1 (L) cells, which had been metabolically labeled with [35S]methionine, were mixed with tumor regressor serum and the immunoprecipitated proteins resolved by electrophoresis through SDS-polyacrylamide gels and visualized by fluorography. Six protein species of molecular mass 115K, 85K, 80K, 65K, 32K, and 15K mol wt were observed in this experiment (Fig. 1, lane b) . The two proteins of 85K and 15K comigrated with the env gene products pr85 e"° and p 15E (Fig. 1, lane c) . The proteins of 85K, 65K, and 15K bear only viral antigenic determinants because the precipitation of these proteins was blocked when unlabeled disrupted M-MuLV virions were added to the immunoprecipitation reaction (Fig. 1, lane a) . Because the proteins of 115K, 80K, and 32K were precipitated in reactions containing exogenous unlabeled MMuLV, these proteins must bear antigenic determinants not shared by M-MuLV To determine whether expression of p 115, p80, and p32 was also observed in clonal lines that no longer expressed the A -M u L V fusion protein p160, the following experiment was performed. E2 cells derived by repeated cloning (40% cloning efficiency) of early passage B6T1 tumor cells were used to initiate a new t u m o r line in genetically distinguishable host mice. After five in vivo transplants, the t u m o r cells, termed E2F1, were placed back into culture and checked for the presence of H-2 or Gpi-1 markers to determine whether the cells were derived from the donor cell population or from the host. E2F1 cells expressed only the H-2 b antigens and Gpi-1 b isoenzyme characteristic of the donor (19) . T h e initial E2 and derivative E2Fx cells were then radiolabeled and examined for synthesis of the A -M u L V gag-fusion protein p160 using anti-gag p15 serum or the p115, p80, p32 molecules detected with antip80 t u m o r regressor serum (Fig. 2) . U n d e r these conditions, p160 a n d pr65 gag were readily detected in E2 cells (Fig. 2, lane b) , whereas no protein was specifically immunoprecipitated from E2 cells with anti-p80 serum (Fig. 2 , lane c). Conversely, pr65 gag but not p160 was detected in E2F1 cells (Fig. 2 , lane e), a n d p80 was readily detected in these cells (Fig. 2 , lane f). Moreover, nucleic acid hybridization experiments indicated that most, if not all, of the A -M u L V proviral genome was lost from E2F1 cells (19) . A similar result was observed when E3 cells were compared with F11A cells, a line derived from E3 after seven in vivo passages. Thus, it is a p p a r e n t that the A -M u L V -e n c o d e d protein p160 a n d the p80 protein, identified with t u m o r regressor sera, bear non-cross-reactive antigenic determinants. An additional feature that distinguished p 160-positive a n d p 160-negative cells was the expression of the Thy-1 differentiation antigen. W h e n the p 160-positive A -M u L V lines E2 a n d E3 were examined in direct cytotoxic tests with monoclonal Thy-1 antibody, the cells were refractory to lysis, whereas F l l A or E2F1 cells, derived from E3 or E2 cells, respectively, showed 95% lysis ( Fig. 3 A a n d data not shown). To confirm the cell surface phenotype of these lines, absorption analysis was performed.
The results of that experiment demonstrate that neither E3 nor E2 cells absorbed cytotoxic activity, whereas FllA cells, E2F1 cells, and thymocytes absorbed all cytotoxic antibody ( Fig. 3 B and data not shown). Therefore, we conclude that E2 and E3 cells have the phenotype p160*, p80-, Thy-1-and that FllA and E2F1 cells have the phenotype p160-, p80 +, Thy-l*.
Comparison of p80 and the A-MuL V-encoded Protein p 120. Serologically, the A-MuLVencoded gag-fusion protein appeared distinct from p80 (Fig. 2) . To confirm the lack of relatedness of p80 to A-MuLV-encoded gag-fusion proteins, the tryptic peptides of p80 were compared with those of the A-MuLV-encoded protein p120 (P120 was selected because larger amounts of it could be recovered and because p 120 and p 160 share 15 tryptic peptides) (19) . After immunoprecipitation with anti-pr65 antiserum from 35S-labeled lysates of 18-4 cells, the gag-fusion product, p 120, was isolated from preparative SDS-polyacrylamide gels. Similarly, p80 was purified by gel electrophoresis of immunoprecipitates from B6TI(L) cells. The two purified proteins were trypsinized in parallel, and their peptides were applied to a sulfonated ion exchange column and eluted with a linear gradient of pyridine acetate (31) . The profile of the methionine-containing peptides of p120 (Fig. 4 , panel C) is quite different from the pattern of the p80 peptides (panel B). Comparison of the methionine-containing peptides of p160 (19) and p80 also demonstrated very different patterns. Thus, from both serological and biochemical analyses, there appears little, if any, homology between p80 and the gag-fusion products of A-MuLV.
The relationship of the three nonviral proteins, p80, p32, and p 115, precipitated from the B6TI(L) cells, was examined. Under nonreducing denaturing conditions, p115 did not appear to be complexed with other proteins (data not shown). Pulsechase analyses indicated that, whereas p115 was not a precursor polyprotein for the smaller proteins, p32 might represent a stable proteolytic product derived from p80 (data not shown). The relatedness of p80 and p32 was confirmed by comparison of their methionine-containing tryptic peptides. Lysates of a~S-labeled B6TI(L) cells were prepared and immunoprecipitated with anti-p80 antiserum. The immune complexes were collected and resolved in preparative SDS-polyacrylamide gels from which p32 and p80 were purified. After trypsinization, p32 (Fig. 4 , panel A) and p80 (panel B) were chromatographed in parallel. The two proteins share several peptides, five of which are noted in Fig. 4 . Because of the difficulty of obtaining sufficient material of p115, a similar comparison with this protein has not been performed. At present the relationship, if any, between p115 and p80 has not been elucidated.
PSO Is a Nonglycosylated Phosphoprotein. B6T 1 (L) cells were incubated in phosphatefree medium supplemented with [aZp]orthophosphate. Extracts of these cells were then immunoprecipitated with either anti-p80 serum (Fig. 5, lane a) or goat anti-pl2 serum (lane b), and the reactive phosphorylated proteins were resolved by gel electrophoresis and visualized by autoradiography. Under these conditions of metabolic labeling, both p80 and pr65 gag appear phosphorylated in these cells; however, p32 does not appear to be.
Although antibodies against p80 are frequently produced after hyperimmunization with many tumor lines, we have no evidence that p80 was expressed at the cell surface. Although the viral glycoprotein (gp70) present at the surface of B6T 1 (L) cells was readily iodinated by the lactoperoxidase method (Fig. 5, lane d) , a technique that specifically radiolabels exposed tyrosine residues of cell surface proteins (33) , no Fie. 4. Comparison of the methionine-containing tryptic peptides of p32, p80, and p120. After immunoprecipitation, the proteins were purified by elution from preparative SDS-polyacrylamide gels. P32 (A), pS0 (B), and p120 (C) were trypsinized in parallel, and their peptides were resolved by chromatography. Labeled peaks represent peptides shared by pS0 and p32. radioactive material was precipitated by either nonimmune B6 or anti-p80 serum (Fig. 5, lanes c and e) . Similarly, the M-MuLV env gene products pr85 env and gp70 could be metabolically labeled in B6T1 (L) cells with [ZH]glucosamine (Fig. 5, lane g ) or [~H]mannose (lane i), but p80 was not labeled with these sugar precursors (Fig. 5,  lanes f and h) . A further indication that p80 was not glycosylated came from experiments in which B6TI(L) cells were incubated with the antibiotic tunicamycin, which inhibits glycosylation. Increasing concentrations of tunicamycin in the medium had a marked effect on the apparent mobility of the env gene products of B6TI(L) cells but did not alter the rate of synthesis nor the mobility of pS0 (data not shown). (Fig. 7) . The pattern of the proteolytic products generated from the p80 proteins of EL4 and R L d l t u m o r cells was similar to that of the p80 protein from B6T1 (L) cells.
PSO Is Synthesized by
The distribution of murine tumors with p80 suggested that this protein did not serve as a generalized marker of transformed cells. A m o n g in vitro cultured cells, p80 has only been detected in cell lines derived from p80-positive t u m o r cells (Table I) genomes of A-MuLV or SFFV, did not synthesize detectable levels of p80 (data not shown). In competition experiments for the 35S-labeled p80 of B6TI(L) cells, nonradioactive lysates of these cells also failed to inhibit precipitation of p80. Similarly, p80 was not detected in RAT-1 cells, SV40 transformed rat embryo fibroblasts, nor secondary cultures of mouse embryo fibroblasts from B6 and BALB/c mice (data not shown). The A-MuLV-transformed lymphoid line 18-4 that synthesized the p 120 gagfusion protein also did not synthesize p80 (data not shown).
Syngeneic and semisyngeneic hyperimmunization with B6TI(L) cells invariably led to the production of p80-reactive antibodies (Table II) * Unless noted otherwise, the expression of the Thy-1 antigen was determined in our laboratory in direct cytotoxicity tests with monoclonal anti-Thy-l.2 antibody. The expression of Thy-1, as reported in reference 20. § The expression of Thy-1, as reported in reference 2 i. marrow, lymph nodes, spleen, and thymus of B6, BALB/c, SWR, and DBA/2 mice were collected and labeled with [aSS]methionine for incubation periods ranging from 2-16 h. In no instance did anti-pS0 antiserum specifically immunoprecipitate a protein of 80,000 tool wt or one serologically related to it from lysates of any of these tissues. Under conditions in which the precipitating activity of anti-pS0 antiserum for the radioactive p80 of B6TI(L) cells was limiting, antiserum was incubated with nonradioactive lysates of cells from B6 lymph nodes, spleen, and thymus before the addition of radioactive tumor cell lysates. The lymphoid extracts were generated from 500-1,000 times the number of B6T I(L) ceils (2 × 10 ~) used as a source of radioactive p80 in these competition experiments. The amount of p80 precipitated was not measurably affected by preincubation of the antiserum with lymphoid extracts (data not shown).
Two populations of rapidly dividing lymphoid cells were examined for synthesis of p80. Regenerating bone marrow cells taken 10 d after reconstitution of lethally irradiated B6 mice did not synthesize p80 (data not shown). Similarly, p80 was not detected in B6 spleen cells that were proliferating (16-fold stimulation of [aH]thymidine uptake) in response to mitomycin C-treated BALB/c spleen cells (Fig. 8 A) .
Reconstruction experiments were performed to determine the synthetic rate of p80 ttg S. aureus V8 protease, and the proteins were subjected to partial enzymatic digestion during electrophoresis through a 15% SDS-polyacrylamide gel.
TABLE II
Sera Tested for the Ability to Precipitate p8O from B6TI (L) Cells
Immunization* Precipitation of pS0:~
1/1 * 8-10-wk-old mice were injected subcutaneously with 10s-10 s tumor cells. After these tumors had regressed, 10-fold increasing numbers of tumor cells were injected intraperitonealty every 2 wk until a dose of l0 s cells per mouse was reached. Thereafter, mice were immunized with 10 s cells. B6 anti-AMuLV was prepared by intravenous inoculation of mice with 104 focusforming units of A-MuLV every 2 wk. With the exception of (C3H × B6)F1 anti-B6T1 (L) antiserum, which was obtained from one mouse, each immunization reflects the pooled sera of 5-10 mice. :~ Data are expressed as the number of independent immunization experiments leading to the production of antibodies that precipitated pS0 per the total number of independent immunizations. § These two antisera do, however, precipitate the A-MuLV gag-fusion proteins through recognition of non-M-MuLV antigenic determinants.
in n o r m a l tissues t h a t w o u l d h a v e b e e n d e t e c t e d b y o u r p r o c e d u r e s (Fig. 8 B) . P a r a l l e l c u l t u r e s of t h y m o c y t e s w e r e l a b e l e d a l o n e or a f t e r m i x i n g w i t h v a r y i n g a m o u n t s o f p 8 0 -p o s i t i v e F x l A cells. P 8 0 a n d p thymus extracts by anti-p80 antiserum but not n o n i m m u n e B6 serum. Reactivity for this 50,000 mol wt species, present in B6Tl(L) cells, has been observed in several pools of anti-p80 antisera. This result is analogous to that of others (15, 16) who also found that p53, a c o m m o n tumor antigen, was synthesized by normal thymocytes. Longer exposures of this fluorogram permit the conclusion that, if p80 were synthesized by normal B6 thymocytes, its synthetic rate in this population of cells would have to have been <0,05% that of its synthetic rate in the p80-positive t u m o r cells.
D i s c u s s i o n
Studies of Abelson l y m p h o m a cells that no longer expressed the A -M u L V transforming protein led to the identification of a protein of ~80,000 tool wt that appears to be coordinately expressed with two minor species of 115,000 a n d 32,000 mol wt in m a n y m u r i n e T cell lymphomas. P80 is phosphorylated but not glycosylated in vivo and is not accessible to lactoperoxidase iodination. A m o n g A -M u L V -i n d u c e d lymphoma cells, p80 has been detected only in those tumors and cell lines that have ceased synthesis of gag-fusion proteins and have acquired a marker usually associated with T lymphocyte differentiation. Several other molecular and phenotypic changes have been observed in these cells (J. Dudley, M. Scheid, C. Spellman, D. J, G r u n w a l d , N. Warner, a n d R. Risser, u n p u b l i s h e d observations), a n d these will be reported in due course.
The association of p80 expression with lymphomas of the T lymphocyte lineage was borne out in the investigation of several murine tumors and cell lines. The 80,000-mol wt proteins synthesized by tumors induced by different agents and from different strains of mice were serologically and biochemically similar. However, not all Thy-1-positive lymphomas synthesized detectable levels of pS0. In addition, pS0 was not detected in established fibroblastic cell lines, whether uninfected, infected with SFFV, or transformed with A-MuLV or SV40. Thus, synthesis of pS0 is not a universal feature of transformed murine or rat cells, but rather it is a common characteristic of murine T cell lymphomas.
The finding that syngeneic immunization with p80 + lymphomas frequently elicited the production of anti-pS0 antibodies suggests that this protein is either not expressed at all or only at very low levels in normal tissues. Competition experiments, designed to detect molecules that might have low synthetic rates in normal tissues, failed to reveal proteins with pS0 antigenic determinants in B6 lymph node, thymus, or spleen tissue. In direct labeling experiments, we never observed immunoprecipitation of p80 from extracts of normal B6, DBA/2, SWR, nor AKR lymphoid tissues. Reconstruction experiments indicated that the level of synthesis of pS0 in a population of adult B6 thymocytes must be <0.05% that of tumor cells. PS0 appears to be unrelated to known or endogenous MuLV-encoded proteins. Serological and biochemical analyses showed that pS0 is not related to the A-MuLVspecific gag-fusion proteins. In most experiments, p80 was detected in immune reactions performed in the presence of an exogenous source of MuLV, such that known MuLV determinants of the tumor ceils were successfully competed. Antisera directed against each of the internal structural proteins of Rauscher MuLV failed to immunoprecipitate pS0, and neither p80 nor p32 included the methionine-containing tryptic peptides of the major M-MuLV structural protein, p30 (unpublished observations).
Although pS0 is distinguishable from other transformation-related proteins, it shares some features with the A-MuLV-encoded gag-fusion protein and with the recently described series of tumor-associated proteins of ~53,000 mol wt (14) (15) (16) . These three sets of proteins have similar physical properties, and all are unglycosylated immunogenic components of the cells in which they are found. Unlike the A-MuLVspecific protein, the presence of pS0 does not correlate with an increased cellular abundance of the amino acid phosphotyrosine. Although E2 cells do have elevated levels of this unusual amino acid, pl60-negative transplanted A-MuLV cells do not (T. Hunter, personal communication). The 53K transformation-related proteins are synthesized in a wide variety of transformed and tumor cells, and these proteins can be readily detected in some normal tissue. The absence of pS0 from normal lymphoid cells and its detection in lymphoid tumors might indicate that pS0 is truly a tumorspecific antigen, or, more likely, that pS0 is normally expressed in some other cell type and frequently activated in lymphoid tumors. Summary Examination of syngeneic tumor regressor sera prepared by immunization of mice with several different lymphomas revealed a common pattern of reactivity to proteins expressed in these tumors. Antibodies present in these sera immunoprecipitate a triplet of proteins of 115,000 mol wt (p115), 80,000 tool wt (p80), and 32,000 mol wt (p32) from many but not all T cell lymphomas of mice. P80, the predominant molecular species immunoprecipitated with these sera, is a nonglycosylated, phosphoprotein that does not appear to be expressed at the cell surface. Comparison of the tryptic peptides of p32 and p80 indicated that the peptides found in p32 are a subset of those found in p80. Comparison of the tryptic peptides of p80 with those of the p120 gag-fusion protein of Abelson murine leukemia virus demonstrated that pS0 and p120 did not share tryptic peptides. Comparison of the partial proteolytic products generated by treatment of pS0 molecules from different tumors with V8 protease did not reveal heterogeneity in p80 among tumors of different strains of mice. Direct labeling and competition blocking experiments with lysates from normal cells failed to provide evidence of p80 synthesis in normal thymus, spleen, or bone marrow. Thus, p80 is a biochemically identified tumor-related antigen of mouse lymphomas.
